RXRX vs ABSI
RXRX and ABSI side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RXRXRECURSION PHARMACEUTICALS, INC. | ABSIABSCI CORP |
|---|---|---|
| Market cap | $2.38B | $1.66B |
| P/S | 33.2x | 644.8x |
| Revenue growth (YoY) | 26.9% | -38.2% |
| Earnings growth (YoY) | -39.1% | -11.7% |
| EBIT margin | -867.9% | -4297.0% |
| ROE | -71.2% | -46.8% |
| ROIC | -181.7% | -84.6% |
| 1y total return | -27.5% | +145.2% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: RXRX frente a ABSI
| Métrica | RXRX | ABSI |
|---|---|---|
| Valor final | $1.1K | $4.5K |
| Retorno total | -89.4% | -55.1% |
| CAGR | -34.6% | -14.1% |
| Volatilidad | 93.2% | 98.3% |
| Sharpe | -0.06 | 0.29 |
| Sortino | -0.10 | 0.43 |
| Caída máxima | -92.1% | -96.2% |
Basado en 1327 días de negociación comunes, 2021-07-22 → 2026-11-02 · tasa libre de riesgo 4.21% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)